Oncolys BioPharma Inc.
Tokyo Stock ExchangeTotal Valuation
Oncolys BioPharma Inc. carries a market capitalization of 69.31B, placing it among publicly traded companies globally. Its enterprise value stands at 10.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 69.31B |
| Enterprise Value | 10.19B |
Share Statistics
Oncolys BioPharma Inc. currently has 20.87M shares outstanding.
| Shares Outstanding | 20.87M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 348.72, and the price-to-book ratio stands at -71.78.
| PE Ratio | N/A |
| PS Ratio | 348.72 |
| PB Ratio | -71.78 |
| P/TBV Ratio | 7.72 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 324.77 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2,539.68 |
Financial Position
Oncolys BioPharma Inc. maintains a current ratio of 7.03, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.82, indicating elevated leverage, while an interest coverage ratio of -454.91 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.03 |
| Quick Ratio | 4.44 |
| Debt / Equity | 25.82 |
| Debt / EBITDA | -0.20 |
| Interest Coverage | -454.91 |
Financial Efficiency
| Return on Equity (ROE) | -619.82 |
| Return on Assets (ROA) | -97.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3.34M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Oncolys BioPharma Inc.'s stock has gained approximately 356.55738% over the past 52 weeks. The 50-day moving average sits at 2,724.40, while the 200-day moving average is 1,876.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | 356.55738% |
| 50-Day Moving Average | 2,724.40 |
| 200-Day Moving Average | 1,876.44 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oncolys BioPharma Inc. generated 31.38M in revenue and converted that into -1.82B in net income, yielding earnings per share of -91.36. EBITDA reached -1.82B, while operating income came in at -1.82B.
| Revenue | 31.38M |
| Gross Profit | 31.38M |
| Operating Income | -1.82B |
| Pretax Income | -1.82B |
| Net Income | -1.82B |
| EBITDA | -1.82B |
| EBIT | -1.82B |
| Earnings Per Share (EPS) | -91.36 |
Balance Sheet
Oncolys BioPharma Inc. holds 1.12B in cash and equivalents against 365.80M in total debt, resulting in a net debt position of -773.10M. Total book value stands at -152.47M, with working capital of 1.52B providing operational flexibility.
| Cash & Cash Equivalents | 1.12B |
| Total Debt | 365.80M |
| Net Debt | -773.10M |
| Equity (Book Value) | -152.47M |
| Book Value Per Share | -7.63 |
| Working Capital | 1.52B |
Margins
Oncolys BioPharma Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5,806.68 and net profit margin of -5,813.83 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -5,806.68 |
| Pretax Margin | -5,803.18 |
| Profit Margin | -5,813.83 |
| EBITDA Margin | -5,806.68 |
Scores
Oncolys BioPharma Inc. posts an Altman Z-Score of 8.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.74 |